The product affected by this notice is sold under the trade name TomoTherapy SharePlan 1.1. To determine if the version you are using is affected, bring up the About box in the SharePlan application and check if the build number reported there is 1.3.1.10. Intended use: t-RayAutoplan is a software that, based on the planned dose distribution from a TomoPlan treatment planning system, generates a family of individually optimized IMRT plans and presents their characteristics to the user in a GUI. Among the generated plans, the user selects and clinically approves a treatment plan and exports it electronically to DICOM, for subsequent treatment of the patient. The intended users of t-RayAutoplan shall be clinically qualified staff, such as medical physicists, medical doctors or dosimetrists
Publicado el 26 de septiembre de 2012 · Inicio del retiro: 30 de mayo de 2011
Resumen
FDA registra el retiro Z-2378-2012 de dispositivos médicos de Clase II, publicado el 26 de septiembre de 2012 e iniciado el 30 de mayo de 2011. Empresa responsable: RAYSEARCH LABORATORIES AB; Estado: Finalizado; Cantidad reportada: 15 units; Lote: SharePlan 1.1, aka t-RayAutoplan version 1.2.1 (build number 1.3.1.10). La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.
Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
This field notice concerns two behaviors of the SharePlan (Multiple Fraction Groups and Depth Offset) that may be unexpected and are not clearly described in the user manual. None of these behaviors have caused patient mistreatment or other incidents. However, the described user actions must be adhered to for best agreement between treatment plan evaluation and the clinical outcome of the delivere
Qué hacer
Voluntary: Firm initiated · Letter
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Fabricante
- RAYSEARCH LABORATORIES AB
- Distribuidor
- Worldwide Distribution - USA including CA, KY, MI, NY, OK, and OR. Internationally to Canada, Belgium, United Kingdom, Australia, France, Germany, and Poland.
- Lote
- SharePlan 1.1, aka t-RayAutoplan version 1.2.1 (build number 1.3.1.10).
- Clasificación de riesgo
- Class II
- Área (FDA)
- device
- País
- Sweden
Retiros relacionados
- FDARayCare 2024A SP4. Oncology Information Systems.8 de julio de 2026
- FDARayCare 2024A SP1. Oncology Information Systems.8 de julio de 2026
- FDABrand Name: RayStation Product Name: RayStation/RayPlan Model/Catalog Number: 14.0.0, 15.0.0, 15.1.3 Software28 de enero de 2026
- FDABrand Name: RayStation Product Name: RayStation/RayPlan Model/Catalog Number: 17.0.0, 17.0.1 Software Version:28 de enero de 2026
- FDABR980-9600 Hysteroscopy Sterile Procedure Kit containing 2 oz. bottle PVP Prep Solution Product Usage: Usage:26 de septiembre de 2012
- FDAHALO Flex Energy Generators Manufactured by B®RRX Medical (now Covidien) 540 Oakmead Parkway Sunnyvale, CA26 de septiembre de 2012
Preguntas sobre este retiro
¿The product affected by this notice is sold under the trade name TomoTherapy SharePlan 1.1. To determine if the version you are using is affected, bring up the About box in the SharePlan application and check if the build number reported there is 1.3.1.10. Intended use: t-RayAutoplan is a software that, based on the planned dose distribution from a TomoPlan treatment planning system, generates a family of individually optimized IMRT plans and presents their characteristics to the user in a GUI. Among the generated plans, the user selects and clinically approves a treatment plan and exports it electronically to DICOM, for subsequent treatment of the patient. The intended users of t-RayAutoplan shall be clinically qualified staff, such as medical physicists, medical doctors or dosimetrists fue retirado del mercado?
Sí. FDA publicó el retiro Z-2378-2012 el 26 de septiembre de 2012. Peligro reportado: This field notice concerns two behaviors of the SharePlan (Multiple Fraction Groups and Depth Offset) that may be unexpected and are not clearly described in the user manual. None of these behaviors have caused patient mistreatment or other incidents. However, the described user actions must be adhered to for best agreement between treatment plan evaluation and the clinical outcome of the delivere
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · Letter